Brief: Algernon Pharmaceuticals Files For Clinical Trial And Ethics Approval For Phase 1 DMT Human Stroke Study
19/01/2022 12:32
Jan 19 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS FILES FOR CLINICAL TRIAL AND
ETHICS
APPROVAL FOR PHASE 1 DMT HUMAN STROKE STUDY
Source text for Eikon: ID:nGNX9g5C0k
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement